Pharmaceuticals

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA

--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assa...

2022-11-23 19:43 5118

Jiangsu Traditional Chinese Medicine International Exchange Conference kicked off in Nanjing

NANJING, China, Nov. 23, 2022 /PRNewswire/ -- On November 21st, the "Jiangsu Traditional Chinese Medicine International Exchange Conference" jointly sponsored by the Foreign Affairs Office of Jiangsu Provincial People's Government and Jiangsu Health Commission kicked off inNanjing. The theme of t...

2022-11-23 14:19 2863

Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand

INDIANAPOLIS, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an ...

2022-11-22 20:00 3112

3Z: Zebrafish mutant model reveals novel drug candidates for ADHD

REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the ...

2022-11-22 10:54 3296

Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology

SUZHOU, China, Nov. 22, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that results from three clinical studies of KN026 (anti-HER2 bispecific antibody) and KN046 (PD-L1/CTLA4 bispecific antibody) will be presented as Spotlight Poster Discussion or Poster Presentation at t...

2022-11-22 09:18 4874

First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with rec...

2022-11-22 04:59 3959

IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer

SYDNEY, Nov. 21, 2022 /PRNewswire/ --  Highlights * Clarity's fifth successful Investigational New Drug (IND) application with theUnited States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin * A total of six products with both the diagnostic and t...

2022-11-21 22:04 4555

Cambrex to Acquire Snapdragon Chemistry, a Leader in Continuous Flow API Development Services

EAST RUTHERFORD, N.J., Nov. 21, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has entered into a definitive agreeme...

2022-11-21 19:00 3769

Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals

VELDONA® interferon-alpha formulation has shown potential as a treatment candidate for feline chronic gingivostomatitis and canine atopic dermatitis Ainos advances its product pipeline as it targets commencing clinical studies during the second quarter of 2023 SAN DIEGO, Nov. 21, 2022 /PRNewswir...

2022-11-21 18:30 2177

OLON, INTERNATIONAL API SUPPLIER, RELEASES THE NEW SUSTAINABILITY REPORT 2022 CONFIRMING THE PROGRESS OF ITS SUSTAINABILITY IN THE FOCUS AREAS OF ENVIRONMENT, SUPPLY CHAIN, PEOPLE, COMMUNITY ENGAGEMENT, PRODUCTION

"Our ambition is to promote a more sustainable production of APIs, meeting the highest standards of quality"Paolo Tubertini, CEO of the Group, commented "To achieve this, we are investing in people, in innovation and technology processes, endorsing the sustainable development goals proposed by th...

2022-11-21 18:00 3132

Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics

CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from "Idea to IND" ("I to ITM"), today announced that it has entered into a collaboration agreement with Dragonfly Therapeutics based on Nona...

2022-11-21 17:31 3691

Lianhua Respiratory Health Products to Assure the Smooth Holding of Hainan International Health Industry Expo

SHIJIAZHUANG, China, Nov. 21, 2022 /PRNewswire/ -- The 6th Hainan International Health Industry Expo kicked off onNovember 18th, in Haikou City, China's Hainan Province. With the theme of "Construct a Global Health System, Draw a Beautiful Future for Hainan Free Trade Port", this year's event wil...

2022-11-21 16:42 3051

Jiangsu Recbio Technology Co., Ltd. Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine

TAIZHOU, China, Nov. 21, 2022 /PRNewswire/ --  (the "Company", together with its subsidiaries, the "Group") on voluntary basis. The board of directors of the Company (the "Board") is pleased to announce that in order to meet the rapidly growing market demand for HPV 9-valent vaccines inChina and ...

2022-11-21 16:07 3937

BGI Group Signs MOUs in Indonesia to Support Genomics Development

SHENZHEN, China, Nov. 21, 2022 /PRNewswire/ -- BGI Group signed three Memorandum of Understandings (MOUs) in the lead up to the G20 Summit inBali with the Indonesian Ministry of Health, the University ofIndonesia and the Del Institute of Technology (Institut Teknologi Del). The MOUs cover geno...

2022-11-21 14:33 3650

Abbott Launches Panbio(TM) HIV Self Test at Retail, Increasing Access to Faster, Reliable and Discrete Testing at Home

* Over-the-counter HIV self-tests can help overcome barriers, including healthcare access and stigma associated with HIV testing, while helping to expand screening * Fast, private and easy-to-use at home, Panbio™ HIV Self Test is a fingerstick blood test that detects HIV-1 and HIV-2 antibodie...

2022-11-21 13:49 8040

MEDICAL CITY CEO NAMED MOST INSPIRING EXECUTIVE AT ACES AWARDS 2022

MANILA, Philippines, Nov. 21, 2022 /PRNewswire/ -- Dr. Eugene F. Ramos, Chief Executive Officer of The Medical City (TMC), was named one ofAsia's most inspiring executives at the Asia Corporate Excellence & Sustainability Awards (ACES) 2022. The award, created to identify successful visionaries a...

2022-11-21 09:00 3578

ACROBiosystems Launches a New Logistics Center in Switzerland to Help Accelerate Drug Development throughout Europe

BASEL, Switzerland, Nov. 18, 2022 /PRNewswire/ -- ACROBiosystems Group has announced the launch of its first European logistics center and warehouse in Basel, Switzerland. This marks the first step towards ACROBiosystems' commitment to globalization by providing swift deliveries to their pharmace...

2022-11-18 20:41 2717

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

- MEDICOX secures distribution right for ORAMED's oral insulin in South Korea after phase 3 of FDA approval - Contract scale up to 18 million dollars for developmental milestone and up to 15% royalty for sales - ORAMED says 1 in 7 Korean adults over 30 have diabetes and expects market potential ...

2022-11-18 17:11 3384

Asia Pacific experts uncover gender-based disparity in diagnosis, treatment, and management of Atrial Fibrillation

A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Nov. 17, 2022 /PRNewswire/ -- Biosense Webster, Inc., part of Johnson & Johnson MedTech[†], today announced the ...

2022-11-17 10:00 4647

Standigm Synthetic Research Center successfully accelerates drug discovery in its first year

Lab uniquely enables collaboration between chemical and AI researchers SEOUL, South Korea, Nov. 16, 2022 /PRNewswire/ -- Standigm , the workflow AI-driven drug discovery company, today announced the celebration of its Synthetic Research Center's first year. In the ...

2022-11-17 08:45 3361
1 ... 270271272273274275276 ... 351